Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Gattermann, N; Finelli, C; Porta, MD; Fenaux, P; Ganser, A; Guerci-Bresler, A; Schmid, M; Taylor, K; Vassilieff, D; Habr, D; Domokos, G; Roubert, B; Rose, C; EPIC study investigators.
Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study.
Leuk Res. 2010; 34(9): 1143-1150.
Doi: 10.1016/j.leukres.2010.03.009
Web of Science
PubMed
FullText
FullText_MUG
- Study Group Mitglieder der Med Uni Graz:
- Linkesch Werner
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The prospective 1-year EPIC study enrolled 341 patients with myelodysplastic syndromes (MDS); although baseline iron burden was >2500ng/mL, approximately 50% were chelation-naïve. Overall median serum ferritin decreased significantly at 1 year (p=0.002). Decreases occurred irrespective of whether patients were chelation-naïve or previously chelated; changes were dependent on dose adjustments and ongoing iron intake. Sustained reductions in labile plasma iron were observed. Discontinuation rate (48.7%) and adverse event profile were consistent with previously reported deferasirox data in MDS. Alanine aminotransferase levels decreased significantly; change correlated significantly with reduction in serum ferritin (p<0.0001). This large dataset prospectively confirms the efficacy and well characterizes the safety profile of deferasirox in MDS.
- Find related publications in this database (using NLM MeSH Indexing)
- Adolescent -
- Adult -
- Aged -
- Alanine Transaminase - blood
- Benzoic Acids - adverse effects Benzoic Acids - therapeutic use
- Blood Transfusion -
- Child -
- Child, Preschool -
- Female -
- Ferritins - blood
- Humans -
- Iron Chelating Agents - adverse effects Iron Chelating Agents - therapeutic use
- Iron Overload - complications Iron Overload - drug therapy
- Male -
- Middle Aged -
- Myelodysplastic Syndromes - complications
- Triazoles - adverse effects Triazoles - therapeutic use
- Young Adult -
- Find related publications in this database (Keywords)
- Myelodysplastic syndromes
- Deferasirox
- Serum ferritin
- Labile plasma iron
- Iron chelation therapy